$JNJ · Johnson & Johnson

Johnson & Johnson filed a Form 4 disclosing transactions by Jennifer L. Taubert, an executive vice president and worldwide chairman of Innovative Medicine. On August 17, 2026, she exercised 15,000 employee stock options at an exercise price of $115.67 per share, acquiring 15,000 shares of common stock. On the same day, she sold those 15,000 shares at a weighted average price of $263.36 per share, with individual trades ranging from $263.30 to $263.48.

Following these transactions, Taubert directly owned 194,451 shares of Johnson & Johnson common stock. She also held 28,712 remaining employee stock options. The exercised options were awarded under the company’s Long-Term Incentive Plan and had an expiration date of February 13, 2027.